×
About 16,126,640 results

American Heart Association Hypertension Guideline Toolkit
http://aha-clinical-review.ascendeventmedia.com/books/aha-high-blood-pressure-toolkit/
American Heart Association

AHA High Blood Pressure Toolkit

FB Live: School's In (Again) -- Reopening Amid the Delta Surge
https://www.medpagetoday.com/infectiousdisease/covid19/94305

Aug 31st, 2021 - Topic: As schools around the U.S. reopen against the backdrop of the Delta variant -- which is causing spikes in hospitalization among kids -- teachers, school boards, and parents are faced with making major decisions about how best to keep children and staff safe. To make matters worse, the politics around back-to-school discussions have gotten messy. Guest: Tina Q. Tan, MD, professor of pedia...

Blood Test Discerns Alzheimer's From Other Dementia With High Accuracy
https://www.medpagetoday.com/neurology/alzheimersdisease/94177

Aug 23rd, 2021 - Two blood markers, phosphorylated tau 217 (p-tau217) and phosphorylated tau 181 (p-tau181), showed strong diagnostic performances for Alzheimer's disease and discriminated Alzheimer's from frontotemporal lobar denervation (FTLD) syndromes and normal cognition, a retrospective study showed. Both plasma biomarkers distinguished Alzheimer's disease syndromes from non-Alzheimer's disease disorders ...

CDC Staff Floats 'Risk-Based Approach' to Potential Booster Doses
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94293

Aug 30th, 2021 - A risk-based booster dose strategy for COVID-19 vaccines could target populations at risk of severe disease and those critical to the public health infrastructure, CDC staff said at a meeting of CDC's Advisory Committee on Immunization Practices (ACIP) on Monday. Though FDA has yet to review data on booster doses for COVID-19 vaccines among the general population, CDC staff presented a prelimin...

Past Infection May Better Protect Against Delta Than Vaccine, but …
https://www.medpagetoday.com/infectiousdisease/covid19/94258

Aug 28th, 2021 - A prior infection from COVID-19 was more protective than vaccine-induced immunity in reducing the risk of infection and symptomatic illness from the Delta variant, according to a retrospective observational study from Israel. Those who received both doses of the Pfizer/BioNTech vaccine in January or February of this year had a 13.06-fold increased risk (95% CI 8.08-21.11) of SARS-CoV-2 infectio...

'Pandemic of the Unvaccinated?' Not Really, Advocate Says
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94211

Aug 25th, 2021 - Is the current COVID-19 surge a "pandemic of the unvaccinated?" No, according to Rhea Boyd, MD, MPH, pediatrician and co-developer of the "The Conversation: Between Us, About Us" project to encourage more people of color to get vaccinated. "This is not a pandemic of the unvaccinated," Boyd said Wednesday at a virtual event sponsored by the Alliance for Health Policy. Instead, "what we really ex...

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness amo...

Alpha1-antitrypsin deficiency: New therapies on the horizon.
https://doi.org/10.1016/j.coph.2021.06.001
Current Opinion in Pharmacology; Remih K, Amzou S et. al.

Jul 14th, 2021 - Alpha1-antitrypsin deficiency (AATD) is caused by mutations in the SERPINA1 gene, coding for alpha1-antitrypsin (AAT). AAT is synthesised mainly in the liver and is released into bloodstream to protect tissues (particularly lung) with its antiprotease activity. The homozygous Pi∗Z mutation (Pi∗ZZ genotype) is the predominant cause of severe AATD. It interferes with AAT secretion thereby leading...

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a ...
https://doi.org/10.1016/j.kint.2021.04.029
Kidney International; Johansen KL, Garimella PS et. al.

May 8th, 2021 - Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) conve...

Obinutuzumab Provides Two-Year Benefits for Lupus Nephritis
https://www.hcplive.com/view/obinutuzumab-two-year-benefits-lupus-nephritis

Nov 4th, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.

Machine Learning Could Benefit Rheumatoid Arthritis Treatment with Sarilumab
https://www.hcplive.com/view/machine-learning-benefit-rheumatoid-arthritis-treatment-sarilumab

Nov 3rd, 2020 - As interleukin receptor (IL) inhibitors, the monoclonal antibody drug class has come to revolutionize fields of inflammatory disease care, though the utility and resourcing of such promising agents is yet to be fully refined. Namely, clinicians can stand to benefit from more biomarkers, more indications by which monoclonal antibodies are most impactful.

ESMO Virtual Congress 2020 Science Weekend Program
https://cslide.ctimeetingtech.com/esmo2020/attendee/confcal/session/calendar

Sep 19th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program

ESMO Guidelines: COVID-19 Adapted Recommendations Slide Sets
https://www.esmo.org/guidelines/covid-19-adapted-recommendations-slide-sets

Sep 19th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Virtual Congress 2020: Exhibition
https://www.esmo.org/meetings/esmo-virtual-congress-2020/exhibition

Sep 19th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.

ESMO: COVID-19 and Cancer
https://www.esmo.org/covid-19-and-cancer?hit=ehp

Sep 19th, 2020 - Updates, guides, webinar series, recommendations, more.

ESMO Webinar Series: Managing Patients in the COVID-19 Era
https://www.esmo.org/meetings/esmo-webinar-series/managing-patients-in-the-covid-19-era

Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

ESMO Virtual Congress 2020: Program
https://www.esmo.org/meetings/esmo-virtual-congress-2020/programme

Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

ESMO Virtual Congress 2020: ESMO Colloquia
https://www.esmo.org/meetings/esmo-virtual-congress-2020/esmo-colloquia

Sep 19th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

ESMO Virtual Congress 2020: FAQs
https://www.esmo.org/content/download/313751/6378320/ESMO-Virtual-Congress-2020-FAQs.pdf

Sep 19th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions